Outcome of Board Meeting held on February 14, 2026 and Submission of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended December 31, 2025 as per SEBI (Listing ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 2.3 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board of ZR2 Bioenergy approved unaudited financial results for Q3 FY26 and the nine-month period ending Dec 31, 2025. Revenue from operations remains nil for the quarter and on a year-to-date basis, with all reported income coming from 'other income' (Rs 41.63 lakhs in Q3 FY26; Rs 140.01 lakhs for 9M FY26). Standalone profit after tax stood at Rs 23.02 lakhs in Q3 FY26 versus a loss of Rs 26.35 lakhs in Q3 FY25, while 9M FY26 PAT was Rs 80.96 lakhs versus a loss of Rs 2.30 lakhs in the prior-year period. The statutory auditor (Bagaria & Co LLP) issued an unqualified limited review opinion on both standalone and consolidated results. The consolidated results include the newly incorporated wholly owned subsidiary ZR2 Solar Private Limited (set up Oct 4, 2024) for the renewable energy business.
The company continues to report zero revenue from operations, so the reported profit is entirely driven by other income rather than core business activity — investors should watch for actual operational revenue from the new solar subsidiary. The unqualified auditor opinion and post-change-of-control restructuring (ZR2 Group Holdings acquired 61% in Dec 2024) suggest a transition phase, but there is no visible operational earnings stream yet.